Table 4. Comparison of combination therapy versus monotherapy.
Outcome | Number of studies | Study name (clinical trial or intervention) | Sample size | Estimated effect size |
---|---|---|---|---|
3.1 Viral load Change (Ct value) from baseline to day 11 vs. placebo | 1 | Gottlieb2021 (BLAZE-1) bamlanivimab/etesevimab vs. bamlanivimab | 418 | MD = −0.61 [−1.11, −0.11] |
Ct, cycle threshold of the reverse-transcriptase–polymerase-chain-reaction assay; MD, mean difference; RR, risk ratio.